[Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders].
Forty one patients with refractory malignant lymphoma were treated with a combination of VP-16, ACM, BH-AC, MTX and PDN as a salvage chemotherapy. These patients were either resistant to frontline therapy or refractory in their relapses. Three patients (7%) achieved a complete remission and 14 patients (34%) attained a partial remission. An overall response rate was 41%. Major toxicities were myelosuppression, nausea, and vomiting. However, they were well tolerated. This regimen has been effective in the treatment for the patients with refractory malignant lymphoma.
Miyazaki
E
E
Second Dept. of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Takemoto
Y
Y
Kanamaru
A
A
Kakishita
E
E
Nagai
K
K
Masaoka
T
T
Shibata
H
H
Horiuti
A
A
Tsubaki
K
K
Yonezawa
T
T
D015250:Aclarubicin / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage
D003561:Cytarabine; D005047:Etoposide; D015250:Aclarubicin; D011239:Prednisolone; C015019:enocitabine; D008727:Methotrexate